Keywords
Dasatinib, chylothorax, pleural effusion
Abstract
Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia. The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional. No case has been reported beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in such scenario. The underlying mechanism is not currently clear. We describe a woman on dasatinib treatment for more than 10 years who developed chylothorax. Drug withdrawal resolved the chylous pleural effusion. We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.
References
![](https://www.ejcrim.com/public/journals/1/submission_3921_3456_coverImage_en_US.jpg)
Views: 408
HTML downloads: 62
PDF downloads: 361
Published:
2023-06-07
Issue:
2023: Vol 10 No 7
(view)